Drug Profile
ASP 5094
Alternative Names: ASP-5094Latest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antirheumatics; Monoclonal antibodies
- Mechanism of Action Integrin alpha9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Adjunctive treatment) in Poland (IV, Injection)
- 28 Mar 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(Adjunctive treatment) in USA (IV, Injection)
- 19 Oct 2018 Pharmacokinetic, pharmacodynamic and adverse events data from a phase I trial in Rheumatoid arthritis presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting